NCT03525392 2023-12-12
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Ipsen
Phase 1 Terminated
Ipsen
Pfizer
InSightec
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Hoffmann-La Roche